Module 7: Chronic Myelogenous Leukemia Treatment Guidelines
This learning activity has been designated for 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- State common side effects associated with imatinib, dasatinib, and nilotinib treatment
- Review the safety data on the tyrosine kinase inhibitors
- Describe effective management of treatment-associated adverse effects in patients with chronic myelogenous leukemia (CML)
Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module